MUC16 and cancer: In addition, anti-ENO1 Ab is also a competent indicator of clinical outcomes in various types of cancer.36, 37, 38, 39, 40 In search of more precise detection results, a panel of four cancer biomarkers was employed, including cancer antigen 125, carcinoembryonic antigen, annexin A1 Abs, and anti-ENO1 Abs for upgraded diagnostic ability.41